10
Views
4
CrossRef citations to date
0
Altmetric
Review

Patent property of suicide gene therapy involving prodrugs 1996 - 1999

&
Pages 1381-1388 | Published online: 25 Feb 2005
 

Abstract

Suicide gene therapy can be defined as a two-step treatment for solid tumours. In the first step, specific gene delivery technology leads to the expression of a foreign prodrug-activating enzyme only in tumour cells. During the second step, a non-toxic prodrug is administered which is converted by the expressed enzyme to a potent cytotoxic agent. The patent literature covering new gene-directed enzyme prodrug therapy (GDEPT) systems, improvements to GDEPT systems and improved delivery for suicide gene therapy, is discussed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.